http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Summit Granted US Patent for Utrophin Modulator SMT C1100 in Treatment of DMD

Oxford, UK, 7 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announces that the United States Patent and Trademark Office has issued patent number 8,501,713 that protects the use of SMT C1100 in treating the fatal muscle wasting disease DMD.

The patent, entitled "Drug Combinations for the Treatment of Duchenne Muscular Dystrophy," covers the combination use of SMT C1100, the small molecule utrophin modulator drug, with corticosteroids such as prednisolone and deflazacort. It provides an exclusivity period until at least February 2029.

Corticosteroids are commonly used in patients to slow the progression of DMD. Summit has shown in the widely used preclinical efficacy model that there is a significant benefit in using prednisolone in combination with SMT C1100. Results from a preclinical fatigue study, analogous to the 6 minute walk distance test used in DMD patient trials, demonstrated that the combined treatment completely protected against fatigue with the treatment group able to travel three and half times the distance of the untreated group. These data have been published in the peer reviewed scientific journal PLoS ONE (Ref: Tinsley et al, Volume 6, Issue 4, May 2011).

"The grant of this US patent covering the use of SMT C1100 in combination with steroids forms part of our broader estate protecting the intellectual property rights of our utrophin modulation programme for DMD," commented Glyn Edwards, Chief Executive Officer of Summit. "This patent estate provides Summit with a commercial advantage from which to exploit the promise of our utrophin modulation programme for the treatment of this devastating disease."

About DMD and Utrophin Modulation
DMD is a progressive muscle wasting disease that affects around 1,500 boys and young men in the UK. It is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of muscles. There is no cure and life expectancy is around the mid-twenties. Utrophin protein is the functional equivalent of dystrophin and non-clinical studies have shown it can substitute for dystrophin to maintain the healthy function of skeletal and cardiac muscle. Utrophin modulation has the potential to slow down or even stop the progression of DMD regardless of the dystrophin mutation. Importantly it is also expected to be complementary to other DMD therapeutic approaches in development.

- END -

More good news..looking even better!

Up 9% :-))

Summit muscular dystrophy drug receives US protection for use in tandem with other treatments
By Ian Lyall August 07 2013, 2:35pm

Audio -

http://www.proactiveinvestors.co.uk/companies/news/59794/summit-muscular-dystrophy-drug-receives-us-protection-for-use-in-tandem-with-other-treatments-59794.html

Looking up.

should start to get alot more positive publicity..this is still another 18+ months from fully achieving it's potential but the momentum is building up nicely! GLA!

Consolidating well! a lot more to come but this is an 18/24month burner.. I'm staying in!..(imho)

Pushing on.

Closed up 11.11%

Nice to see the gradual increase in the SP continuing,,,,I've now doubled my outlay on this from when I went in April last year... I even bought it through the old Hoodless Brennan.. makes a change for an HP rec doesn't ?!... still staying though for time being.

Sold a few of these.

:-))

Yes - thanks for these - I bought in @5.5.

I owe you some well dones skinny, so well done on these. :-)) Lets hope they get back to the highs of the past.

Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 8.13. Over this period, the share price is up 160.00%.

:)

Closed up 10.77%.


Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 9.14. Over this period, the share price is up 204.65%.

Summit Corporation PLC : Notice of Interim Results

HUG


Summit Corporation plc
('Summit' or 'the Company')

NOTICE OF INTERIM RESULTS

Oxford, UK, 21 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, will announce its interim results for the six months ended 31 July 2013 on Thursday, 22 August 2013.

Summit Corporation PLC : Interim Financial Results

HUG


Summit Corporation plc
("Summit" or "the Company")

INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 JULY 2013

Oxford, UK, 22 August 2013, Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, today reports its interim financial results for the six months ended 31 July 2013.

HIGHLIGHTS

Product Development



Duchenne Muscular Dystrophy ('DMD')
•
Phase 1b patient clinical trial of SMT C1100 on-track to start in H2 2013

•
Activities supporting clinical DMD programme progressing well and include the initiation of novel biomarker programme and drug product manufacture

•
Programme Advisory Board established to support scientific and clinical development of DMD programme


C. difficile Infection ('CDI')
•
Positive results from Phase 1 clinical trial in healthy volunteers showed novel antibiotic SMT 19969 to be safe and well tolerated in this study

•
Encouraging data from Phase 1 trial about future efficacy and specificity of SMT 19969 with results showing it was highly sparing of gut flora bacteria

•
Preparations to commence patient clinical trials in H1 2014 progressing well


Corporate
•
New funding secured from broad range of sources including £4.6 million fund raise with new and existing investors and £2.4 million grant from UK Biomedical Catalyst Fund

•
Dr Frank Armstrong appointed as Non-Executive Chairman with Dr Barry Price taking up a Non-Executive Director role

•
Strengthening of clinical development team including the appointment of Dr David Roblin as Chief Medical Officer


Financial
•
Cash position at 31 July 2013: £6.0 million (31 July 2012: £4.8 million)

•
Operational expenditure in-line with expectations

•
Net loss for the six months ended 31 July 2013 £2.1 million (31 July 2012: £2.2 million)


Glyn Edwards, Chief Executive Officer of Summit commented: "It has been an excellent period for Summit during which our strategy of focusing on the development of our clinical-stage DMD and C. difficile programmes has made substantial scientific progress and also received broad financial support."



"We now look forward to advancing clinical trials into patient populations for both the DMD and CDI programmes to further evaluate these potential life-changing treatments for two serious diseases."



- END